| ARMP Stock | | | USD 2.01 0.02 1.01% |
CEO
Deborah MD is CEO Director of Armata Pharmaceuticals
| Age | 68 |
| Address | 5005 McConnell Avenue, Los Angeles, CA, United States, 90066 |
| Phone | 310 665 2928 |
| Web | https://www.armatapharma.com |
Armata Pharmaceuticals Management Efficiency
The company has return on total asset
(ROA) of
(0.2457) % which means that it has lost $0.2457 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(34.3935) %, meaning that it created substantial loss on money invested by shareholders. Armata Pharmaceuticals' management efficiency ratios could be used to measure how well Armata Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/20/2025,
Return On Equity is likely to grow to 2.03, while
Return On Tangible Assets are likely to drop
(0.99). As of 03/20/2025,
Total Current Liabilities is likely to grow to about 19.9
M. Also,
Liabilities And Stockholders Equity is likely to grow to about 118.8
MArmata Pharmaceuticals currently holds 120.37
M in liabilities with Debt to Equity
(D/E) ratio of 0.73, which is about average as compared to similar companies. Armata Pharmaceuticals has a current ratio of 5.48, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Armata Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It has a partnership agreement with Merck Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. Armata Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 69 people. Armata Pharmaceuticals (ARMP) is traded on NYSE MKT Exchange in USA. It is located in 5005 McConnell Avenue, Los Angeles, CA, United States, 90066 and employs 66 people. Armata Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Armata Pharmaceuticals Leadership Team
Elected by the shareholders, the Armata Pharmaceuticals' board of directors comprises two types of representatives: Armata Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Armata. The board's role is to monitor Armata Pharmaceuticals' management team and ensure that shareholders' interests are well served. Armata Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Armata Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Martin, Advisor | |
| Richard Rychlik, VP Controller | |
| Todd MBA, Advisor | |
| Pierre Kyme, Senior Development | |
| Peter Hubbard, Vice Operations | |
| MS MD, Chief Officer | |
| Duane BA, VP Operations | |
| Wenyuan Shi, CoFounder Scientist | |
| David House, Senior Officer | |
| Deborah MD, CEO Director | |
| Brian Varnum, CEO Director | |
| Bryan Kadotani, Vice Operations | |
| Erin Butler, Principal Admin | |
Armata Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Armata Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to
measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to
predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.